The Homing Mechanism
When regenerative biologics are delivered intravenously, they don't simply circulate passively through the bloodstream. They actively seek out areas of inflammation and cellular stress — a phenomenon researchers call homing — engaging the body's natural renewal processes across immune function, cognitive performance, and metabolic health.
Mesenchymal stem cells possess a remarkable ability to migrate toward sites of tissue damage and inflammation. This is mediated by a class of signaling molecules called chemokines, which are released by injured or inflamed tissue. The stem cells express receptors for these chemokines, allowing them to follow the chemical gradient to the precise location where repair is needed.
Systemic vs. Targeted Effects
When delivered intravenously, the biologics first pass through the pulmonary circulation — the lungs — where a significant portion are temporarily sequestered. This pulmonary first-pass effect is not a limitation but a feature: the lungs are a major site of immune regulation, and the interaction between the biologics and pulmonary immune cells appears to modulate systemic inflammation in ways that contribute to the whole-body effects patients report.
The distinction between IV therapy and targeted injection is not one of superiority but of application. Injection therapy delivers a concentrated dose to a specific anatomical site — ideal for discrete joint or tissue pathology. IV therapy delivers biologics systemically, making it the appropriate choice for conditions that are diffuse rather than localized: systemic inflammation, immune dysregulation, accelerated aging, cognitive decline, and chronic fatigue.
What Patients Experience
Many patients choose IV therapy as a complement to injection therapy — addressing both the specific site of damage and the broader systemic environment that may be contributing to it. Others choose IV therapy as a standalone longevity and optimization protocol, seeking the whole-body regenerative effects without a specific pathological target.
The IV infusion itself takes approximately 60 to 90 minutes in our private clinic environment. Patients typically report feeling relaxed during the infusion, with no significant discomfort. The biologics are delivered through a standard IV line at a controlled rate, with vital signs monitored throughout.
Dosing and Protocol
In the days following the infusion, some patients report a mild fatigue — a sign that the immune system is actively engaging with the biologics and initiating repair processes. This typically resolves within 24 to 48 hours. The more notable effects — improvements in energy, cognitive clarity, sleep quality, and recovery — tend to emerge over the following two to eight weeks. Individual results may vary.
At CellRX, IV therapy is priced at $1,250 per CC, with protocols ranging from 1 CC to a maximum of 10 CC based on the patient's condition, goals, and the Medical Director's clinical assessment. The starting price for IV therapy is $4,000. Every biologic carries full chain of custody — never diluted, never replicated, always from healthy, consented local births under direct physician oversight.
Who Benefits Most
The optimal dosing protocol is determined during your private consultation. Some patients benefit from a single high-dose infusion; others achieve better outcomes with a series of lower-dose infusions spaced over several months. Your Medical Director will design the protocol that best matches your biology and goals.
IV stem cell therapy is particularly well-suited for individuals experiencing the effects of accelerated biological aging, chronic systemic inflammation, post-COVID syndrome, autoimmune conditions, chronic fatigue, and cognitive decline. It is also increasingly chosen by high-performing executives and athletes as a proactive longevity investment — not in response to a specific pathology, but as a strategy for maintaining peak biological function. Individual results may vary. These statements have not been evaluated by the FDA.